Logo for Daily Business Review

More Litigation Coming? Insulin MDL Gets Boost from FTC Report

By Lisa Willis

Jan 17, 2025

Tal J. LifshitzBenjamin J. Widlanski

Insulin MDL litigation is gaining momentum, bolstered by a fresh FTC report. Tal Lifshitz and Ben Wotlanzki emphasize that the agency’s findings reinforce allegations of anticompetitive behavior and pricing manipulation. They predict a surge in lawsuits targeting insulin manufacturers, setting the stage for intensified legal scrutiny and robust multidistrict litigation activity.

Click here to read the original article.